Brokerages Set $10.50 Target Price for Check Cap Ltd (NASDAQ:CHEK)

Check Cap Ltd (NASDAQ:CHEK) has been assigned an average broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Brokers have set a 12 month consensus price target of $10.50 for the company and are expecting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also assigned Check Cap an industry rank of 74 out of 256 based on the ratings given to related companies.

CHEK has been the topic of a number of analyst reports. Zacks Investment Research upgraded HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Beyondspring in a research report on Wednesday, July 10th.

Shares of NASDAQ:CHEK traded up $0.05 during trading on Friday, reaching $2.09. 357,733 shares of the company’s stock traded hands. Check Cap has a fifty-two week low of $1.62 and a fifty-two week high of $4.50. The stock has a 50-day simple moving average of $2.21.

Check Cap (NASDAQ:CHEK) last posted its earnings results on Monday, May 13th. The medical research company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.03. As a group, equities research analysts expect that Check Cap will post -1.69 earnings per share for the current year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Recommended Story: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.